TG Therapeutics, Inc. Announces Presentation of Interim Results from its Phase I/II Clinical Trial of Single-Agent Ublituximab (TG-1101) in Patients with Rituximab Relapsed/Refractory Non-Hodgkin's Lymphoma TG-1101 Well

TG Therapeutics, Inc. Announces Presentation

of Interim Results from its Phase I/II Clinical Trial of Single-Agent Ublituximab (TG-1101) in Patients with Rituximab Relapsed/Refractory

Non-Hodgkin's Lymphoma

TG-1101 Well Tolerated and Induced 50%

Overall Response Rate (5/10)

40% of Rituximab-Refractory

Patients (2/5) Achieve a Complete Response

Zone Lymphoma Patients (3/3) Achieve a Complete or Partial Response

New York, NY, (June 3, 2013) - TG Therapeutics,

Inc. (TGTX) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients

with rituximab relapsed and/or refractory Non-Hodgkin's Lymphoma (NHL), presented at the American Society of Clinical Oncology

Meeting on June 2, 2013. The poster presentation, entitled "A Phase I dose-escalation trial of ublituximab (TG-1101), a novel

anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients," was presented by Principal

Investigator, Dr. Owen A. O'Connor of Columbia University (Abstract #8575). The poster is available on the Company's

website (www.tgtherapeutics.com) under the quick links section entitled "Publications."

PRELIMINARY DATA FROM THE DOSE ESCALATION PORTION OF PHASE

The poster presentation highlighted preliminary safety and efficacy

data from 4 cohorts of 3 patients each at dose levels of 450mg, 600mg, 900mg and 1200mg. All 12 patients (7 Follicular (FL), 3

Marginal Zone (MZL) and 2 Mantle Cell Lymphoma (MCL)) were evaluable for safety while 10/12 patients were evaluable for efficacy

(2 patients were too early for efficacy evaluation (TETE)). Among these 12 patients, the median number of prior therapies was 4

(range 2-6), with 100% and 75% of patients receiving at least 1 and 2 prior rituximab-based regimens, respectively. Fifty percent

(50%) of enrolled patients were considered refractory to a rituximab-based regimen, defined as progressing on or within 6 months

following their last rituximab-based regimen.

Ublituximab (TG-1101) was well tolerated with the majority of

adverse events being Grade 1 and 2, with minimal Infusion Related Reactions (IRR) observed. Only one Grade 3 event was reported.

All 12 patients completed all planned infusions. Infusion time decreased significantly from the first (mean of 4 hours) to the

fourth and maintenance infusions (mean of ~ 1.5 hours).

The summary of response data is described below:

Abbreviations: Complete Response (CR); Partial Response (PR);

Stable Disease (SD); Progressive Disease (PD); Overall Response Rate (ORR); To Early to Evaluate (TETE); Rituximab (RTX)

Median Progression-Free Survival (PFS) has not been reached.

Responses were observed in both rituximab relapsed and refractory patients, including patients who have seen several lines of rituximab

therapy. Of the 5 patients enrolled that were refractory to rituximab, 2 patients (40%) achieved a CR. Decreases in overall tumor

volume were seen in 9/10 of the evaluable patients. Notably, 100% (3/3) of patients with Marginal Zone Lymphoma responded to ublituximab

(TG-1101) therapy, two of which achieved a CR. Among the 5 responding patients, all achieved a response that was better than (n=4)

or equal to (n=1) their prior rituximab-based treatment:

+ Patients still on study with continuing response

Commenting on the Phase I data, Dr. Owen A. O'Connor,

Director of Lymphoid Malignancies, Professor of Medicine and Experimental Therapeutics at Columbia Medical Center, New York Presbyterian

Medical Center in NY, and Study Chair for the Phase I trial stated: "We are very impressed with the activity we've

seen to date with ublituximab, especially with complete responses in patients who achieved a less than optimal response to rituximab,

including patients with Marginal Zone Lymphoma, a subtype known to be a low CD20 expressing tumor. Ublituximab has been very well

tolerated at all dose levels allowing patients to benefit from higher ublituximab doses and maintenance dosing without compromising

Michael S. Weiss, the Company's Executive Chairman and

Interim Chief Executive Officer added, "While these results are early, we are very encouraged by the high observed response

rates as well as the quality of such responses in terms of durability and in comparison to each patient's prior rituximab

- based treatment, many of which included multi-drug regimens. These data are also consistent with the high response rates seen

in our CLL Phase 1 study, previously reported. We look forward to aggressively recruiting patients to the expansion cohorts of

this single agent TG-1101 study in order to better define the safety and efficacy demonstrated in this dose-escalation group, and

to presenting data from these expansion cohorts at the American Society of Hematology meeting at the end of this year."

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is an innovative, clinical-stage biopharmaceutical

company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment

of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101

(ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the

CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The

delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation

and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies.

TG Therapeutics is headquartered in New York City.

Cautionary Statement

the statements included in this press release, particularly those anticipating future clinical trials and business prospects for

TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements,

we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform

Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully

and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early clinical results that

supported our decision to move forward into expansion cohorts will not be reproduced once additional patients are treated with

TG-1101; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced

from prior pre-clinical and clinical trials; our ability to achieve the milestones we project over the next year; our ability to

manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the

Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of

this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that

occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com.

The information found on our website is not incorporated by reference into this press release and is included for reference purposes

Director- Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4484

Email: ir@tgtxinc.com